• Policy
• Scemblix is listed in July
• by Lee, Tak-Sun Jun 23, 2023 05:45am

• Policy
• Expansion of # of members of the Committee to around 105
• by Lee, Tak-Sun Jun 22, 2023 05:43am

• Policy
• New drug pre-registration - post-evaluation non-face-to-face
• by Lee, Jeong-Hwan Jun 22, 2023 05:41am

• Policy
• MFDS cautious about strengthening regulations
• by Lee, Jeong-Hwan Jun 22, 2023 05:40am

• Policy
• Imported orphan drug specimen storage standards
• by Lee, Hye-Kyung Jun 22, 2023 05:40am

• Policy
• 85% of the public requests more coverage for severe diseases
• by Lee, Jeong-Hwan Jun 21, 2023 05:52am

• Policy
• Mandatory benefit for Erleada impact?
• by Lee, Tak-Sun Jun 20, 2023 05:36am

• Policy
• Negotiations between Verquvo and Retevmo begin
• by Lee, Tak-Sun Jun 20, 2023 05:36am

• Policy
• Rationalization of expedited review of new pharmaceuticals
• by Lee, Hye-Kyung Jun 20, 2023 05:35am

• Policy
• 100 billion won more for new drug 500 billion won megafund
• by Lee, Hye-Kyung Jun 19, 2023 06:00am